Anti-VEGF Bevacizumab (Avatin®) for Radiation Optic Neuropathy

Purpoe To evaluate intravitreal bevacizumab treatment for radiation optic neuropathy (RON). Deign Interventional cae report. Method At The New York Eye Cancer Center, a patient ymptomatic of decreaed viion becaue of RON wa treated with intravitreal bevacizumab (1.25 mg). Main outcome meaure included viual acuity, appearance of the optic nerve, fundu photography, angiography, and optical coherence tomography/canning laer ophthalmocopy (OCT/LO). Reult Within one week, her viion improved from 20/32 to 20/20 with a reduction in optic dik hemorrhage. At ix week, evidence of both decreaed hemorrhage and optic dik edema wa documented by photography, angiography, and OCT/LO. At the three and five-month follow-up viit, the hemorrhage reolved, and her dik margin were harp. There were no ocular or ytemic ide effect. Concluion Intravitreal bevacizumab wa tolerated, improved viion, and reduced hemorrhage a well a optic dik edema (angiographic leakage). Anti-VEGF therapy (e.g. bevacizumab) hould be invetigated for both ocular and nonocular radiation neuropathy.